Monomeric destetrapeptide human insulin from a precursor expressed in Saccharomyces cerevisiae.
Destetrapeptide insulin (DTI, human insulin with B27-30 removed) was obtained from a monomeric precursor (MIP) expressed in Saccharomyces cerevisiae through tryptic transpeptidation in the presence of synthetic tetrapeptide Gly-Phe-Phe-Tyr. The in vivo biological activity of DTI, determined by mouse convulsion assay, is 22 IU/mg. Its binding activity with insulin receptor on human placental membrane is 80% and its in vitro biological activity, determined by free fat cell assay, is 77%. Compared with native insulin, DTI molecules do not associate in solution but exist in the monomeric form, thus leading to its rapid utilization in vivo.
Cui
D F
DF
Shanghai Institute of Biochemistry, Institutes for Biological Sciences, Chinese Academy of Sciences.
Li
M Y
MY
Zhang
Y S
YS
Feng
Y M
YM
D000595:Amino Acid Sequence; D001483:Base Sequence; D002853:Chromatography, Liquid / Q000379:methods; D006801:Humans; D007328:Insulin / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics* / Q000302:isolation & purification* / Q000378:metabolism; D011384:Proinsulin / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000302:isolation & purification; D012441:Saccharomyces cerevisiae / Q000235:genetics*
D007328:Insulin; D010446:Peptide Fragments; D011994:Recombinant Proteins; D011384:Proinsulin